Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.

New Protocol: Ipilimumab + Nivolumab for MSI-H Colorectal Cancer
Phase 3, multicenter, open-label, randomized clinical trial (CheckMate 8HW) Unresectable or metastatic colorectal cancer with MSI-H/dMMR status, across all treatment lines Nivoluma
New Reference: Trastuzumab Emtansine in HER2-Positive Breast Cancer with Residual Disease
Phase 3, multicenter, randomized, controlled trial (KATHERINE) HER2-positive early breast cancer with residual invasive cancer after neoadjuvant therapy T-DM1 vs. trastuzumab (14 c
New Reference: Periop FLOT in Esophageal Cancer
Phase 3, multicenter, randomized, controlled trial (ESOPEC) Esophageal or GE junction adenoCa, cT1cN+, cT2–4a cN+, or cT2–4a cN0 FLOT (perioperative chemotherapy) vs. preoperat
New Drug: Datopotamab Deruxtecan for HR+, her2 Neg Breast Cancer
Phase 3, open-label, randomized study (TROPION-Breast01) Inoperable or metastatic HR+/HER2– breast cancer, previously treated with 1 or 2 lines of chemotherapy in the inoperable/
New Protocol: Acalabrutinib with R-Bendamustine for Mantle Cell Lymphoma
Randomized, double-blind, placebo-controlled, multicenter trial (ECHO) Previously untreated Mantle Cell Lymphoma (MCL) who were ineligible for transplant (N=598) Acalabrutinib + R-
New Drug: Cosibelimab for Cutaneous SCC
Open-label multicenter, phase I trial (NCT03212404) Metastatic or locally advanced cutaneous SCC Cosibelimab 800 mg q2wks (n=78)
New Drug: Zenocutuzumab for advanced NRG1 fusion positive NSCLC and Pancreatic Cancer
Multi-center, open lavel study (eNRGy) NRG1 fusion positive NSCLC (n=64) and pancreatic adenocarcinoma (n=30) with disease progression after standard therapy
New Indication: Durvalumab for Limited Stage SCLC
Phase 3, randomized, double-blind, placebo-controlled trial, multicenter Limited-stage small-cell lung cancer (LS-SCLC) after chemoradiation Durvalumab vs. placebo
New Drug: Zolbetuximab with FOLFOX for Gastric and GE Junction Cancer
Phase 3, multicenter, randomized, double-blind trial (SPOTLIGHT) Locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, CLDN18.2-positive,
Easiest Access to Our Chemotherapy Protocol Library
Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries